Plain-English translation of NCT06079671 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help women with locally advanced cervical cancer who have finished standard chemotherapy and radiation treatment. The medication works by helping the immune system recognize and fight cancer cells. Researchers want to know if adding this treatment after standard care can improve outcomes and keep cancer from coming back.
Even after chemotherapy and radiation, some cervical cancers can return or continue to grow. This trial exists to see if this medication—which boosts the immune system's ability to fight cancer—can help prevent that from happening and give women better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either or a placebo (inactive substance) after completing your standard chemotherapy and radiation. You will visit the study clinic regularly for monitoring, blood tests, and assessments to see how well the treatment is working and to check for any side effects. The study involves about 800 women worldwide and will track your health over time to compare how the new medication affects cancer outcomes.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States